Chapter 23: Osteoporosis and Evaluation of Fracture Risk

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

So a single bone density scan can actually predict a patient's risk of fracture more accurately than hypertension predicts the risk of a stroke.

I mean that is a wild statistic to start with.

Right.

Welcome to the Deep Dive.

We are stepping in as your audio clinical preceptors today.

That's right.

You are mastering women's health assessment, specifically the evaluation of fracture risk.

And our mission here is to take some incredibly dense clinical data from the text and translate it into plain student friendly language.

Exactly.

We're going to walk you right down the clinical pathway.

So going from history taking and physical exams all the way to diagnostic testing, interpretation

and finally management.

And that statistic about predicting fractures, I feel like that's the perfect anchor for this entire discussion.

It really is.

I mean we constantly talk about hypertension as the silent killer in cardiovascular health.

Yeah.

Well osteoporosis is the silent disease of the skeleton.

Yeah silent until something breaks.

Exactly.

It's a skeletal disorder characterized by low bone mass and compromised bone strength, which obviously leads to porous bones and a highly increased risk of fracture.

And just to establish a critical baseline right away.

This is a generalized disease, right?

It affects all skeletal sites.

Yes, all sites, though it usually begins at the wrist and then it progresses to the vertebrae and finally down to the hip.

You know, to really grasp the pathophysiology here, I always like to think of bone remodeling as an ongoing road repair project.

Oh, I like that analogy.

Yeah.

So you have these two main crews working on the highway of your skeleton.

You have the demolition crew,

the osteoclasts acting like jackhammers to break down old damaged bone.

Right.

And then following right behind them, you have the construction crew, the osteoblasts.

Exactly.

They act like the pavers laying down fresh new bone matrix.

And for most of our lives, these crews work in perfect sync.

But osteoporosis happens when the jackhammers start working faster than the pavers.

Yes.

The old bone gets cleared away, but the new bone just isn't laid down fast enough to replace it.

So the road gets dangerously thin.

That is exactly what happens on a cellular level.

And the scale of the damage that results from that imbalance is just massive.

Give us the numbers.

How big of a problem is this?

We are looking at 2 .3 million fractures annually in the U .S.

and Europe alone.

That costs over $23 billion.

Wow.

23 billion.

Yeah.

And one in two women over the age of 50 will suffer a fracture secondary to osteoporosis.

One in two.

That's half of all women over 50.

It is.

And the hip fractures are particularly devastating.

The mortality rate associated with hip fractures is 12 to 20 % during the very first year following the injury.

That is a staggering mortality rate for a broken bone.

And even for those who survive, fewer than half ever return to their pre -fracture level of function.

Great.

So it isn't just a broken bone for an older adult.

It is a catastrophic loss of independence.

Completely.

I mean, their relative risk for a hip fracture is actually equal to their combined risk for breast, uterine, and ovarian cancers.

Yeah.

Okay, but wait.

There's a counterintuitive point in the clinical data that I think we really need to unpack here.

Oh, regarding where most fractures actually occur.

Yeah.

The text explicitly states that a patient's fracture risk is significantly higher when their bone mass hits the severe osteoporosis level.

Right.

The lower the density, the higher the individual risk.

But then it also notes that the absolute majority of all fractures actually occur in women with only mild to moderate bone loss, the category we call osteopenia.

Right, which sounds contradictory at first.

Let me just think through the math on that.

Because if their bones are technically stronger than someone with osteoporosis, they shouldn't be breaking more frequently.

It's entirely a population numbers game.

Okay, so like an individual woman with severe osteoporosis obviously has a much higher personal risk of breaking a bone.

Right.

But there is a massive pool of women walking around in the general population who fall into that milder osteopenia category.

Oh, I see.

Because that pool of people is so enormous, the sheer volume of fractures coming from that group ends up eclipsing the severe category.

You hit the nail on the head.

And that population math is exactly why proactive screening is non -negotiable.

You can't just sit around waiting for severe osteoporosis to develop.

Exactly.

You have to catch the osteopenia early.

Okay, so let's bring this into the clinic.

You're sitting with a patient.

You're taking their history.

What red flags tell you the jackhammers are outpacing the pavers?

Well, structurally, we are looking for a slight build with a loss of body fat.

Also early menopause or an estrogen deficiency, right?

Yes.

And lifestyle factors play a huge role.

High caffeine intake, excessive alcohol consumption, and smoking.

Eating disorders are a big one to screen for too.

They are.

But the red flag that requires immediate clinical attention is long -term steroid therapy.

Yeah, let's talk about that because glucocorticoid use changes the entire landscape of bone health.

It really does.

You specifically need to ask if they have been on a medication like prednisone at a dose of 5 milligrams or more for longer than three months.

And you'll see this history a lot in patients managing things like rheumatoid arthritis or chronic lung disease, right?

Very frequently.

And the reason steroids are so detrimental is that they directly suppress your pavers, the osteoblasts.

Oh, while simultaneously extending the lifespan of your jackhammers, the osteoclasts.

Exactly.

Plus, they decrease calcium absorption in the gut.

So it's basically a triple threat to bone density.

That explains the mechanism perfectly.

And speaking of gut absorption, you also need to ask about conditions that cause intestinal malabsorption.

Right, like celiac disease.

Yeah, or a history of gastric bypass surgery.

If they have those, they simply aren't absorbing the necessary calcium and vitamin D from their diet to hand over to the construction crew.

Right.

So once you finish the history, you move to the physical exam.

And because osteoporosis is silent, you really have to know what subtle clues to look for visually.

We mentioned earlier that fractures usually progress from the wrist to the spine to the hip.

Yeah, and vertebral fractures are actually twice as common as hip fractures.

About 700 ,000 happen annually.

The textbook says up to two -thirds of those spinal fractures are completely asymptomatic and painless.

They are.

So how do you catch a painless fracture in a routine exam?

You grab a tape measure.

Because these are spontaneous compression fractures of the thoracic vertebrae, the spine literally starts to collapse inward on itself.

So you are looking for a historical loss of 1 .5 inches in height.

Exactly.

That 1 .5 inches is a massive clinical indicator.

As the front of the vertebrae crush down, the spine curves, resulting in a forward bending of the upper spine.

You'll often hear this referred to as a dowager's hump.

Right.

And if the disease progresses to advanced stages without intervention,

the physical distortion becomes extreme.

How extreme?

Well, with severe height loss in the thoracic spine, the ribs actually descend downward.

They can eventually come to rest right on the pelvic bone.

Oh, wow.

The ribs resting on the pelvis.

Yeah.

And because the thoracic cavity is now severely compressed, it forces downward pressure on the internal organs, pushing the stomach outward.

So a patient might come in complaining of gastrointestinal issues or bloating or just feeling wider around the middle.

Exactly.

But the root cause is actually a collapsing skeletal structure.

That is a terrifying image.

But I guess it highlights exactly why we need to move from physical examination to diagnostic testing the moment we spot these signs.

Absolutely.

And the gold standard for this is the central dual energy X -ray absorbed geometry scan.

Which we thankfully just call the DXA scan.

Much easier to say.

Let's break down the procedure and the math for the students.

Yeah, because a lot of patients here bone scan and they immediately picture an MRI tube, right?

They do.

And you need to be able to reassure them.

The DXA scan is incredibly simple.

It takes about 10 to 15 minutes.

So they aren't enclosed in anything.

Not at all.

The patient simply lies flat on an open table while an imager passes over their body.

It is completely painless.

And it measures bone density in grams per square centimeter, usually focusing on the hip, the spine, and the forearm.

Correct.

And all that data revolves around one key metric.

The T -score.

Okay, let's explain the P -score.

Think of it as a bell curve comparing your patient to healthy young adults.

Right.

It measures standard deviations, or SDs, from the average peak bone mass of a healthy young adult woman.

So if that T -score comes back at negative 1 .0 or higher, they are in the normal range.

Yep.

Normal bone density.

If it dips between negative 1 .0 and negative 2 .5, that is low bone mass, which gives you the diagnosis of osteopenia.

And if it is negative 2 .5 or lower, you have a formal diagnosis of severe osteoporosis.

Okay, but I want to add a critical caveat there that the text emphasizes.

The clinical event override.

Yes.

If your patient has had a low trauma fragility fracture, say they trip while walking on a flat sidewalk, fall from a standing height, and shatter their wrist.

Then they have severe osteoporosis regardless of what that bone mineral density score says.

Exactly.

The clinical event overrides the imaging math.

But you know, the T -score is just a snapshot of the bone density at that exact second.

Right.

It doesn't tell us where the patient is heading in the future.

And that's where the F -R -A -X tool comes in.

The Fracturist Assessment Tool.

It's a 10 -year algorithm developed by the World Health Organization.

It takes the bone density from a very specific site, the femoral neck, and stirs in all those demographics and clinical risk factors we gathered in the history.

Things like age, weight, smoking status, family history, steroid use.

Exactly.

It crunches all that data and spits out a 10 -year probability of the patient suffering a fracture.

So what are the clinical thresholds for the F -R -A -X tool in the U .S.?

They are very specific.

You diagnose osteoporosis and initiate pharmacological treatment if their 10 -year probability for a major osteoporotic fracture is 20 % or higher.

Or… Or you treat if their probability for just a hip fracture is 3 % or higher.

Okay.

20 % major, 3 % hip.

Got it.

Now let's talk about the clinical traps with the DxA scan.

Are there times we absolutely should not put a patient on that table?

Pregnancy is the only absolute contraindication due to the radiation.

Even though the dose is extremely low, we just don't risk it.

But there are anatomical traps, too, right?

Things that can ruin your data.

Yes.

If a patient has orthopedic hardware in their spine or hip, or a severe spinal deformity, the machine cannot scan that area accurately.

So you have to measure elsewhere, like the radius of the wrist.

Exactly.

What about arthritis?

I'd imagine extra bone growth from osteoarthritis would completely confuse the scanner.

It absolutely does.

If a patient has severe spinal arthritis in their lumbar spine, the calcium deposits and bone spurs act like armor.

Oh.

So they look incredibly dense to the x -ray.

Right.

The DxA machine gets tricked and kicks back a T -score that lives falsely elevated.

Meaning it looks healthier than the actual underlying bone really is.

Yes.

So we have to look at the whole picture.

If the T -score looks suspiciously great, but the patient has lost more than 1 .5 inches of height,

we can't just trust the DxA.

We need a vertebral fracture assay, or VFA, alongside it.

Exactly.

It's a specialized scan of the spine to evaluate vertebral height directly.

And the beauty of the VFA is that it can often be done on the same DxA machine right at the same time without adding significant radiation risk.

Okay.

So who actually gets screened?

What are the guidelines?

The Bone Health and Osteoporosis Foundation guidelines are clear.

You recommend bone mineral density testing for all women age 65 and older, and all men age 70 and older.

But we also test post -menopausal women and men age 50 to 69 if they present with the specific risk factors we outlined earlier, right?

Correct.

Like a slight build, steroid use, smoking, things like that.

Okay.

Let's say we scan a patient, they have a T -score of negative 2 .6, and we start treatment.

I know with things like blood pressure, we check back in a few months.

How often are we putting this patient back on the DxA table to see if the meds are working?

Well, bone remodeling is a slow, structural process.

You won't see changes in months.

So how long do we wait?

You perform a follow -up DxA one to two years after initiating therapy to monitor its effectiveness.

And if they are untreated?

Say they just have mild osteopenia and we're just monitoring.

Then you rescan them every two to five years.

And there is a major rule regarding follow -ups that you must follow.

What's that?

You must advocate for using the exact same machine, the same facility, and ideally the same technologist for every single scan.

Really?

Why is that so rigid?

Is there really that much variance between machines?

Massive variance.

DxA machines have known precision errors.

Oh, I see.

Yeah, if a patient gets their baseline scan on a Hologic machine at one hospital and their follow -up on a GE machine at a different clinic, the calibration differences can completely mask bone loss.

Or falsely suggest bone gain.

You're basically comparing apples to oranges.

Exactly.

So stick to the same machine.

Okay.

Let's shift into interpretation and management.

Before we even look at prescription drugs, we have to ensure the construction crew, the osteoblast, actually have the raw materials they need to build bone.

Right.

Foundational nutrition, dietary supplements.

The text provides a very clear cutoff age for nutritional requirements, and that age is 50.

So what are the numbers?

If the patient is under 50, they need 1 ,000 milligrams of calcium and 400 to 800 IUs of vitamin D daily.

Then once they cross that age 50 threshold?

The requirements jump.

To 1 ,200 milligrams of calcium and 800 to 1 ,000 IUs of vitamin D.

Perfect.

Foundational nutrition is vital, but for many patients in the osteoporotic range, just handing them calcium isn't going to fix the underlying imbalance between the demolition and construction crew.

I have to move to pharmacology.

We do.

And this introduces a highly unique management concept called the drug holiday.

Yeah, a drug holiday.

I mean, in almost every other chronic disease like diabetes or heart failure,

once a patient is on a maintenance medication, they stay on it.

Generally, yes.

So why would we intentionally take a high -risk patient off their osteoporosis medication?

It comes down to the mechanism of our first -line drugs, the anti -resorptive agents, primarily bisphosphonates.

These drugs work by basically poisoning the demolition crew.

They bind to the bone, and when an osteoclast tries to break that bone down, the drug shuts the cell down.

Which stops bone loss.

That sounds great.

It is great, but remember, remodeling is a healthy, necessary process.

Over years, microcracks develop in our skeleton just from daily living.

Normally, the demolition crew clears out those microcracks so the construction crew can patch them.

But if you completely suppress bone turnover for too long, the bone becomes dense, but it also becomes brittle.

It becomes unable to repair its own microdamage.

Exactly.

And the text highlights two severe, terrifying complications of that frozen remodeling process.

The first one is osconecrosis of the jaw, or ONJ.

And why the jaw specifically?

Well, think about it.

The jaw takes massive, constant mechanical stress from chewing every single day.

It requires rapid cellular turnover to repair those tiny daily micro traumas.

Right.

So if bisphosphonates freeze that turnover, a simple dental procedure or an extracted tooth can suddenly result in exposed, dying jawbone that refuses to heal.

It's awful.

And the second major risk is atypical subtrochanteric fractures.

What are those?

These are catastrophic fractures of the femur that happen completely out of nowhere, often while the patient is just walking without any trauma.

Wow, just from walking.

Yeah.

The frozen remodeling means tiny stress fractures in the thigh bone build up over years without being repaired until the bone just suddenly snaps under normal weight.

Okay, so because of these risks, providers initiate a drug holiday, a one - to two -year break from the medication to let the bone wake up and heal itself.

Exactly.

And how do you time that holiday?

Well, for a patient with mild risk, you might consider pausing the medication after five years of treatment.

And for a high -risk patient?

You push that window and wait until six to ten years of stability.

For 5 -e -dolidronic acid specifically, it's three years for high risk and up to six years for very high risk.

But we need to make sure you hear this next rule loud and clear.

Drug holidays only apply to the bisphosphonate class.

You never initiate a drug holiday with non -bisphosphonates.

Never.

So, let's quickly run through the decision pathways for these drugs because as an advanced practice student, you need to know exactly when to use them and when to avoid them.

We just talked about the bisphosphonates like weekly oral alendronate, which is Fosamax, or the yearly phidea infusion of zolidronic acid reclassed.

They are highly effective.

But what is the absolute hard stop for this class?

The kidneys.

All bisphosphonates heavily impact renal function.

They are absolutely contraindicated if the patient's estimated the merolar filtration rate, their GFR, drops below 30 to 35 milliliters per minute.

You cannot use this class if the kidneys are failing.

So what's the pivot?

If the kidneys are compromised, you might pivot to a wrinkle ligand inhibitor, like dinosumabab, also known as prolia.

This is a subcutaneous injection given every six months, right?

Yes.

And it works differently.

Osteoblasts naturally secrete a protein called RNKL, which acts as a signal to activate the osteoclasts.

And dinosumabab intercepts that signal.

Exactly.

It's an antibody that intercepts the signal, keeping the osteoclasts asleep.

But that mechanism is exactly why you have to be so careful.

You have to monitor their serum calcium closely, because keeping those cells asleep can cause hypercalcemia.

True.

And more importantly, you must remember this prescriber warning.

Dinosumabab should never, under any circumstances, be discontinued abruptly.

What happens if a patient misses their injection or stops cold turkey?

The neutralizing antibody disappears, and all those suppressed osteoclasts wake up at once in a massive rebound effect.

Oh, so they aggressively dissolve bone.

Yes, causing a severe risk of multiple spontaneous vertebral fractures.

Wow.

OK, so we have drugs that stop the breakdown of bone.

But what if a patient has severe osteoporosis, and we need to actually build new bone mass rapidly?

For that, we look at the anabolic agents,

specifically the parathyroid hormone or PTH analogs, like periparotide or abalaparotide.

These are daily subcutaneous injections, right?

Yes.

They essentially hand megaphones and extra materials to the osteoblast, forcing them into overdrive to lay down thick new bone.

But you can't leave them in overdrive forever.

The strict rule with PTH analogs is a maximum lifetime use of two years.

And when managing side effects, you need to warn patients about orthostatic hypotension.

Right.

Because of the vascular effects, you should instruct them to sit or lie down immediately if they feel dizzy after injecting their dose.

But the primary mechanism of these drugs,

rapidly accelerating cellular replication to build bone,

brings us to their absolute contraindication.

You must not prescribe PTH analogs to any patient with an increased risk for osteosarcoma, which is bone cancer.

Exactly.

That includes patients with Paget's disease of the bone,

anyone with unexplained elevations in serum alkaline phosphate.

Or importantly, anyone who has had prior radiation therapy involving the skeleton.

The accelerated cell turnover combined with prior radiation damage is a recipe for malignancy.

So what if your patient needs an anabolic agent to build bone, but they do have a history of skeletal radiation?

The text provides a newer alternative.

An anti -sclerostin agent called romosazumab, or evenity.

Right.

Sclerostin is a protein that naturally halts bone formation, so blocking it lets the bone grow.

And this one can be used in patients with prior radiation exposure.

It's a monthly injection given for a maximum of one year.

But it has its own massive warning label.

You have to watch the heart.

Romosazumab carries a black box warning for cardiovascular risk.

So you shouldn't use it in patients who are at high risk for cardiovascular events or who have had a myocardial infarction or a stroke within the previous year.

Correct.

Okay, we have one final class to cover.

CIRMS, Selective Estrogen Receptor Modulators.

The primary one here is Riloxapine, or Avista.

This medication binds to estrogen receptors in the bone to mimic the protective effects of estrogen, slowing down bone loss without stimulating breast or uterine tissue.

It is FDA approved specifically for the prevention and treatment of vertebral fractures.

And it's a great option for younger post -menopausal women.

But it comes with a trade -off.

By interacting with estrogen receptors, it can cause severe hot flashes.

And far more critically, it significantly increases the risk of deep vein thrombosis, venous thromboembolism, and death from stroke.

We've covered the entire clinical pathway today, from identifying the slight build patient on steroids to measuring their spine, catching the dowager's hump, running the DXA and algorithms,

and navigating this really intense pharmacological minefield.

And as you prepare to integrate this into your clinical practice, I want you to consider the unique psychological challenge of managing this disease.

Yeah!

You are going to be sitting across from patients who feel completely fine.

They have no pain, no symptoms, no idea their skeleton is hollowing out.

And your job is to convince them to take powerful medications, drugs with rare but terrifying side effects, like johnacrosis or sudden femur fractures, just to prevent a future event they can't even imagine yet.

That requires immense trust.

And that trust is built entirely on your competence.

When you understand exactly how the jackhammers and pavers operate, when you can clearly explain why a patient needs a drug holiday, or why they absolutely cannot abruptly stop their dinosumab, you bridge that gap.

You take a single scan, look years into their future, and use the exact tools required to change it.

Thank you for joining the Last Minute Lecture Team for this deep dive into women's health assessment.

Keep looking for those silent signs, and we'll see you next time.